MEDIX, God. 23 Br. 126  •  Pregledni članak  •  Ginekološka endokrinologija HR ENG

Jesu li se promijenili stavovi o primjeni HNL-a u žena koje su preboljele rak dojkeHave the attitudes on the use of hormone replacement tharapy been changed in women who have had breast cancer?

Višnja Matković

Hormonsko nadomjesno liječenje (HNL) jedino je uspješno liječenje žena s postmenopauzalnim tegobama. Poznato je da estrogen i progesteron mogu biti promotori tumorskoga rasta, osobito u stanicama dojke, no do danas nije dokazano da oni uzrokuju rak dojke. Rak dojke najčešći je tumor u žena, posebno u razdoblju od 40. do 60. godine života. Već niz godina onkolozi ne preporučuju HNL ženama koje su preboljele rak dojke, iako istraživanja potvrđuju da u nekih bolesnica korist od primjene HNL-a može nadmašiti rizik za ponovnu pojavu bolesti. S druge strane, pozitivna obiteljska anamneza posebno u žena nosioca BRCA1/2 mutacija ima znatan utjecaj na incidenciju raka dojke pa u žena koje imaju bliske srodnice s rakom dojke treba biti oprezan u propisivanju HNL-a te razmisliti o drugim nehormonskim mogućnostima prevencije postmenopauzalnih tegoba.

Ključne riječi:
hormonsko nadomjesno liječenje; povratak bolesti; rak dojke

Članak u cijelosti pročitajte u tiskanom izdanju MEDIX, God. 23 Br. 126

Hormone replacement therapy (HRC) is the only successful treatment for women with postmenopausal disorders. It is known that estrogen and progesterone can be tumor growth promoters, especially in breast cells, but it has not been proven that they cause breast cancer. Breat cancer is the most common neoplasm in women, especially between the ages of 40 and 60 years. For many years, oncologists have not recommended HRC for women who have had breast cancer, although studies confirm that in some patients the benefit from HRC administration may outweigh the risk of a new disease. On the other hand, a positive family history, especially in women with BRCA1/2 mutations, has a significant influence on breast cancer incidence. Thus, women with close relatives who had breast cancer should be careful in taking HRC and consider other, non-hormonal options for the prevention of postmenopausal disorders.

Key words:
breast neoplasms; hormone replacement therapy; recurrence